typical microdose of tirzepatide 3- Month Micro-dosing Tirzepatide |

Individuals with a history of certain cancers, untreated thyroid disease, severe gastrointestinal disorders, or a personal/family history of medullary thyroid carcinoma may not be candidates for specific medications

The right medication for you depends on personal preference

Any foodservice strategy that does not account for this cohort is working with incomplete information

Maryland patients quickly notice fewer cravings and reduced hunger

Noninvasive, microbiome-based diagnosis of inflammatory bowel disease

Clinical studies of incretin receptor agonists provide evidence of cardiovascular benefit, but they do not directly demonstrate anti-fibrotic effects, as fibrosis has not been measured as a primary outcome in major trials